A Phase IIb Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Disease Save

Date Added
January 9th, 2018
PRO Number
Pro00074247
Researcher
Julie Kanter washko

Silhouette
Keywords
Blood Disorders
Summary

This study is for patients 18 years and older who have Sickle Cell Disease. The study will be evaluating the safety and tolerability of treatment with riociguat to potentially improvement in blood pressure, blood circulation, and disease symptoms. Participants can expect to be in this study for 20 weeks.

Institution
MUSC
Recruitment Contact
Emily Warner
843-876-8614
warnere@musc.edu

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-?0 Thalassemia) Save

Date Added
January 9th, 2018
PRO Number
Pro00074278
Researcher
Julie Kanter washko

Silhouette
Keywords
Blood Disorders
Summary

This is for patients aged 18 and older who have Sickle Cell Disease. The main purpose of this study is to find out how safe IMR-687 is for treating people with Sickle Cell, and whether it is has any unwanted effects. Participation in this study will last about 8 months.

Institution
MUSC
Recruitment Contact
Emily Warner
843-876-8614
warnere@musc.edu

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis Save

Date Added
October 24th, 2017
PRO Number
Pro00071740
Researcher
Julie Kanter washko

Silhouette
Keywords
Blood Disorders
Summary

This study will assess the efficacy of crizanlizumab in sickle cell disease patients. The study is for male and female subjects between the ages of 18 to 70 who have experienced at least one pain crisis within a 12 month period. The drug is given via an IV infusion in an outpatient setting and consists of 52 visits.

Institution
MUSC
Recruitment Contact
Emily Warner
843-876-8614
warnere@musc.edu

A Family-Centered Self-Management Program for Young Children with Sickle Cell Disease: Phase II Save

Date Added
September 7th, 2017
PRO Number
Pro00068250
Researcher
Shannon Hudson

Silhouette
Keywords
Blood Disorders, Children's Health, Infant, Pediatrics
Summary

This study tests an intervention to help children with sickle cell disease ages 0-7 years and their families. The intervention is available on a smartphone or tablet, and includes an app for keeping track of symptoms and messaging with a health care provider. For more information, please contact Shannon at 843-792-9379.

Institution
MUSC
Recruitment Contact
Shannon Phillips
843-792-9379
phillipss@musc.edu

Self-Management for Families and Youth Living with Sickle Cell Disease - SMYLS Save

Date Added
September 2nd, 2017
PRO Number
Pro00062837
Researcher
Shannon Hudson

Silhouette
Keywords
Blood Disorders, Children's Health, Pediatrics
Summary

The purpose of this study is to find out whether a web-based intervention using a mobile device over a 12-week period is helpful in managing symptoms of Sickle Cell Disease in children, such as pain and fatigue and quality of life. For more information, please contact Shannon at 843-792-9379.

Institution
MUSC
Recruitment Contact
Shannon Phillips
843-792-9379
phillipss@musc.edu

Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina and South Carolina Save

Date Added
August 22nd, 2017
PRO Number
Pro00064785
Researcher
Julie Kanter washko

Silhouette
Keywords
Blood Disorders
Summary

The purpose of this project is to utilize implementation science to evaluate patient and system outcomes associated with the dissemination of a toolbox of decision support tools designed based on the NHLBI evidence-based guidelines for treating individuals with sickle cell disease (SCD). These tools will be disseminated to primary care physicians and emergency department providers across NC and SC. The overarching goal is to implore provider education and the implementation of a co-management model of care to improve the efficiency and quality of healthcare for individuals with SCD. The co-management model of care suggests that individuals with SCD benefit from visiting both their primary care clinician and their SCD specialist twice per year.

Institution
MUSC
Recruitment Contact
Ashley Green
843-876-8652
greenan@musc.edu

Implementation of a Sickle Cell Enhanced Novel Care Network in South Carolina (iSCENSC): Needs Assessment and Registry Protocol Save

Date Added
August 8th, 2017
PRO Number
Pro00066242
Researcher
Cathy Melvin

Silhouette
Keywords
Blood Disorders
Summary

iSCENSC is a three-part study that will use new methods (called implementation science) to identify ways to enhance care for people with sickle cell disease (SCD) who are in the (SC)2 South Carolina Sickle Cell network. The (SC)2 network is designed to help more people with SCD find a doctor with training in sickle cell disease and to improve their medical care. Part one of the study is a needs assessment where we look at the current barriers for people with SCD. Part two is a registry for individuals with SCD; and part three will be a study or studies to try and help improve the care for individuals with SCD.

Institution
MUSC
Recruitment Contact
Ashley Green
843-876-8652
greenan@musc.edu

A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion Save

Date Added
August 8th, 2017
PRO Number
Pro00068449
Researcher
John Lazarchick

Silhouette
Keywords
Blood Disorders, Drug Studies, Rare Diseases
Summary

This is a first-in-humans gene therapy study for subjects diagnosed with severe hemophilia A. A one time infusion of the gene therapy product (BAX888) will be given with the hope of eliminating or reducing the need for prophylactic and/or on-demand use of FVIII concentrate therapy. Up to 10 subjects will be enrolled study-wide with up to two subjects enrolled at MUSC. This study will require weekly visits to the study clinic after initial infusion for the first 15 weeks followed by monthly visits for the first year. Compensation will be provided.

Institution
MUSC
Recruitment Contact
Lauren Card
843-792-5935
cardl@musc.edu

Evaluation of the CytoRADx SystemTM as a Biodosimeter for Special Human Populations Save

Date Added
July 14th, 2017
PRO Number
Pro00067066
Researcher
Gary Headden

Silhouette
Keywords
Blood Disorders, Children's Health, Environmental Factors, HIV / AIDS, Non-interventional, Pediatrics
Summary

This is a study to develop a test for radiation exposure in the event of a nuclear event such as the detonation of a nuclear device or widespread radiation exposure. We will collect blood samples from a variety of different types of human subjects whose current medical status could possibly have an effect on the results of the test, such as trauma, burns, infections or a damaged immune system or young children. The goal is to ensure that these conditions do not affect the results of the test.

Institution
MUSC
Recruitment Contact
Robert Houck
(843) 792-3576
houckr@musc.edu

Risk and Resistance Factors for Depression and Anxiety among Youth with Sickle Cell Disease Save

Date Added
June 14th, 2017
PRO Number
Pro00066397
Researcher
Laura Reinman
Keywords
Adolescents, Anxiety, Blood Disorders, Depression, Mental Health
Summary

The this study will examine how fatigue level impacts symptoms of depression and anxiety among adolescents with SCD on a daily basis. It will further examine how cognitive appraisal of stress and self-concept moderate the relationship between fatigue and symptoms of depression and anxiety among adolescents with SCD on a daily basis to better understand mechanisms driving internalizing in this population.

Institution
Palmetto
Recruitment Contact
Laura Reinman
803-997-0366
lreinman@email.sc.edu

Change_preferences

-- OR --

Create_login